ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2025
Characterization and Clinical Implications of p53 Dysfunction in Patients With Myelodysplastic Syndromes.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Article
- Molecular-Based Ecosystem to Improve Personalized Medicine in Chronic Myelomonocytic Leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Article
- Real-world, multi-omics validation of the clinical relevance of molecular taxonomy for myelodysplastic syndromes (MDS).HemaSphere · 2026Article
- Therapy of high-risk myelodysplastic syndromes.Bone marrow transplantation · 2026Review
- Cooccurrence of myelodysplastic neoplasm and myeloid sarcoma with background mediastinal germ cell tumor: an autopsy case.Journal of clinical and experimental hematopathology : JCEH · 2026Article
- The pathogenesis of therapy-related myeloid neoplasms from TP53-mutant clonal hematopoiesis.Leukemia · 2026Article
- Myelodysplastic syndrome progress to acute myeloid leukemia: new insights and updates.Frontiers in immunology · 2026Review
- Clinical and Biological Insights into Myelodysplastic Neoplasms Associated with Deletions of Chromosome 5q Region.Hematology reports · 2025Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
51 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTumor Protein 53 (p53) expressed from gene PATIENTS AND
methodsWe analyzed a cohort of 6,204 patients with MDS and subsets of patients with available information on RNA sequencing of tumor cells (n = 109), high-dimensional phenotype of immune cells (n = 77), and multiomics analysis (RNA sequencing and proteomics) on single cells (n = 15). An independent validation was performed on 914 patients.
resultsBiallelic
conclusionThe identification of nonmutational p53 dysfunction in MDS may lay the foundation for a mechanistic classification of myeloid neoplasms, moving beyond a purely molecular stratification. The recognition of patients with p53 dysfunction is relevant to provide correct disease-risk assessment and interventions, as well as to refine the design of clinical trials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.